CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
